Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.34 |
| ▸ | CDK2 | P24941 | 11/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.34 |
| ▸ | MTOR | P42345 | 3/20 | 0.32 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.32 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 4/20 | 0.31 |
| ▸ | LCK | P06239 | 2/20 | 0.31 |
| ▸ | HCK | P08631 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 2/20 | 0.31 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | KIF5B | P33176 | 2/20 | 0.31 |
| ▸ | ETV6 | P41212 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | CCDC6 | Q16204 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10234923 | 0.90 | CHEK1 (0.34) | CHEK1CCNA2CDK2CCNA1MTOR | |
| SCHEMBL10240146 | 0.89 | MTOR (0.41) | CHEK1CCNA2CDK2CCNA1MTOR | |
| SCHEMBL10240054 | 0.88 | CHEK1 (0.34) | CHEK1CCNA2CDK2CCNA1MTOR | |
| SCHEMBL7886260 | 0.86 | CHEK1 (0.40) | CHEK1CCNA2CDK2CCNA1MTOR | |
| SCHEMBL10240048 | 0.85 | LCK (0.37) | MTORRPTORMLST8KDRLCK | |
| SCHEMBL10240045 | 0.84 | PIK3CA (0.35) | CHEK1MTORRPTORMLST8KDR | |
| SCHEMBL10240035 | 0.82 | CYP11B2 (0.32) | CHEK1MTORRPTORMLST8 | |
| SCHEMBL10234881 | 0.82 | CHEK1 (0.34) | CHEK1CCNA2CDK2CCNA1MTOR | |
| SCHEMBL7882675 | 0.82 | KDM4E (0.38) | CHEK1CCNA2CDK2CCNA1KDR | |
| SCHEMBL10238135 | 0.80 | TYRO3 (0.36) | CHEK1CCNA2CDK2CCNA1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.